Table 2.

Characteristics of Patients with Incident Sarcoidosis

	PWH	Without HIV	P Value
No.	59	265
Demographics
Age at diagnosis, y	50 ± 9	47 ± 11	.06
Male sex, %	100	93	.03
Race, %			.13
White	18	26
Black	79	65
Hispanic	2	7
Other	2	2
Smoking status			.39
Current	32	33
Former	21	14
Never	47	53
CD4 closest to diagnosis, %
≥500 cells/mm3	34	-
350–499 cells/mm3	30	-
300–349 cells/mm3	9	-
100–299 cells/mm3	27	-
HIV-1 RNA closest to diagnosis, %
≤500 copies/mL	76	-
500–10 000 copies/mL	12	-
≥10 000 copies/mL	12	-
Stage of pulmonary involvement at diagnosis (Scadding criteria), %			.07
0	26	22
I	32	36
II	17	27
III	19	14
IV	6	1
Organ involvement in first year, %
Lung/mediastinum	88	86	.67
Skin	27	17	.71
Eye	10	11	.86
Liver	5	7	.56
CNS	3	1	.10
Exocrine (eg, parotid gland)	2	3	.67
Peripheral lymph node	5	6	.91
Bone or bone marrow	2	1	.72
Gut	3	1	.10
Heart	0	2	.60
Spleen	3	4	.89
Kidney	0	0.4	>.99
No. of involved organs in first year, %			.54
1	63	66
2	27	23
3	8	8
4	2	0
Treatments in first year
Use of systemic corticosteroids, %	34	35	.84
Total dose of corticosteroids, mg prednisone equivalents	2195	1800	.97
Use of steroid-sparing immunosuppressants, %	5	10	.22
Baseline PFTs
No.	27	111
FVC, L	3.3 (2.9–4.5)	3.6 (3.2–4.4)
FVC, % predicted	76 (67–93)	79 (69–89)	.73
FEV1, L	2.5 (2.3–3.5)	2.8 (2.3–3.3)
FEV1, % predicted	75 (63–96)	75 (67–87)	.85
DLCO, mL/min/mmHg	18 (14–22)	21 (16–27)
DLCO, % predicted	64 (54–77)	72 (56–82)	.34
TLC, L	5.5 (4.7–6.2)	5.4 (4.7–6.1)
TLC, % predicted	80 (68–94)	83 (73–94)	.47

PFT values assessed within 1 year of diagnosis of sarcoidosis.

Abbreviations: CNS, central nervous system; DLCO, diffusion limit for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PFT, pulmonary function test; PWH, people with HIV; TLC, total lung capacity.